TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28004415

Group type: EXPERIMENTAL
Intervention: High-density lipoprotein (HDL)
Number of subjects: 2323

Group type: EXPERIMENTAL
Intervention: Cholesterol : high-density lipoprotein ratio
Number of subjects: 2323

Group type: EXPERIMENTAL
Intervention: Total cholesterol and low-density lipoprotein (LDL)
Number of subjects: 2323

Group type: EXPERIMENTAL
Intervention: Total cholesterol
Number of subjects: 2323
Study: 25607117

Group type: EXPERIMENTAL
Intervention: Listening to jazz music (BPM <100) for 30 min in the PACU (n=28)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Wearing noise-canceling headphones for 30 min in the PACU (n=28)
Number of subjects: 56
Study: 24727078

Group type: EXPERIMENTAL
Intervention: Individual Cognitive Behavioral Therapy (ICBT)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavioral Therapy (GCBT)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT) combined (ICBT and GCBT)
Number of subjects: 182
Study: 21901395

Group type: EXPERIMENTAL
Intervention: Adjuvant anthracycline-based dose-dense sequential chemotherapy
Number of subjects: 595

Group type: COMPARATOR
Intervention: Adjuvant anthracycline-based dose-dense sequential chemotherapy with paclitaxel
Number of subjects: 595
Study: 20813593

Group type: EXPERIMENTAL
Intervention: Cefazedone 500 mg IV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cefazedone 1000 mg IV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cefazedone 2000 mg IV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cefazedone
Number of subjects: 0
Study: 17985009

Group type: EXPERIMENTAL
Intervention: Enhanced secondary prevention program
Number of subjects: 2643

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2643
Study: 15923569

Group type: EXPERIMENTAL
Intervention: Carboxyaminoimidazole (CAI) 250 mg/d
Number of subjects: 368

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Carboxyaminoimidazole (CAI)
Number of subjects: 368
Study: 11970938

Group type: EXPERIMENTAL
Intervention: Structured letters
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional letters
Number of subjects: 32
Study: 9809381

Group type: EXPERIMENTAL
Intervention: Creatine (15 g/d)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Creatine (2 g/d)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 7654159

Group type: EXPERIMENTAL
Intervention: Decreased perceived responsibility
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Increased perceived responsibility
Number of subjects: 30
Study: 2439782

Group type: EXPERIMENTAL
Intervention: Bisoprolol (10 to 20 mg)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Atenolol (50 to 100 mg)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 94
Study: 29178659

Group type: EXPERIMENTAL
Intervention: Behavioral Weight Loss (BWL) intervention for 16 weeks
Number of subjects: 110

Group type: COMPARATOR
Intervention: Migraine Education (ME) control for 16 weeks
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Behavioral Weight Loss (BWL) intervention
Number of subjects: 110

Group type: COMPARATOR
Intervention: Migraine Education (ME) control
Number of subjects: 110
Study: 27999280

Group type: EXPERIMENTAL
Intervention: Craigslist
Number of subjects: 2149

Group type: EXPERIMENTAL
Intervention: Word of mouth
Number of subjects: 2149

Group type: EXPERIMENTAL
Intervention: Facebook
Number of subjects: 2149

Group type: EXPERIMENTAL
Intervention: Flyers or postcards
Number of subjects: 2149

Group type: EXPERIMENTAL
Intervention: Interpersonal contact
Number of subjects: 2149

Group type: COMPARATOR
Intervention: Newspaper ads in California
Number of subjects: 2149

Group type: COMPARATOR
Intervention: Staff in-person recruiting in North Carolina
Number of subjects: 2149
Study: 24944041

Group type: EXPERIMENTAL
Intervention: Ketoconazole (400 mg/day for 7 days) with PF-04449913 (200 mg single dose on day 4)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-fat meal with PF-04449913 (200 mg single dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: PF-04449913 alone (200 mg single dose)
Number of subjects: 0
Study: 22348605

Group type: EXPERIMENTAL
Intervention: Tapentadol 75 mg t.d.s. for 48 h
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Oxycodone 5 mg t.d.s. for 48 h
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 20122630

Group type: EXPERIMENTAL
Intervention: Training group G2 (dissemination of SEPAR guidelines)
Number of subjects: 1481

Group type: EXPERIMENTAL
Intervention: Training group G3 (dissemination of SEPAR guidelines and distribution of Koko Peak Pro)
Number of subjects: 1481

Group type: COMPARATOR
Intervention: Control group G1 (usual clinical practice)
Number of subjects: 1481

Group type: COMPARATOR
Intervention: Control group G1 vs Training group G3
Number of subjects: 1481
Study: 18718471

Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg/day)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 18491553

Group type: EXPERIMENTAL
Intervention: Intraoperative face‐based surface registration
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Feature PBR
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Cortical vessel‐contour registration
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Unconstrained geometric/intensity registration
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Constrained geometric/intensity registration
Number of subjects: 11
Study: 15039691

Group type: EXPERIMENTAL
Intervention: Supine with epigastric pressure
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Supine
Number of subjects: 65

Group type: COMPARATOR
Intervention: Leg raise
Number of subjects: 65

Group type: COMPARATOR
Intervention: Semirecumbent position
Number of subjects: 65

Group type: COMPARATOR
Intervention: Sitting position
Number of subjects: 65
Study: 11505114

Group type: EXPERIMENTAL
Intervention: Postpyloric enteral feeds
Number of subjects: 33

Group type: COMPARATOR
Intervention: Gastric enteral feeds
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Gastroesophageal regurgitation
Number of subjects: 33
Study: 9106787

Group type: COMPARATOR
Intervention: 20% fat emulsion formulation
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 2% formulation enriched 10-fold with phospholipids
Number of subjects: 50
Study: 8149250

Group type: EXPERIMENTAL
Intervention: Radiotherapy (7000 cGy in 47 days or 7500 cGy in 54 days)
Number of subjects: 372
Study: 3520619

Group type: EXPERIMENTAL
Intervention: Local antibacterial agents (variety of local antibacterials)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: 5 percent povidone-iodine (50 percent Betadine) solution
Number of subjects: 124
Study: 31584922

Group type: EXPERIMENTAL
Intervention: Telehealth appointment for cast removal (group B)
Number of subjects: 52

Group type: COMPARATOR
Intervention: In-person cast removal at institution (group A)
Number of subjects: 52
Study: 30230266

Group type: COMPARATOR
Intervention: 150 M PLX-PAD
Number of subjects: 20

Group type: COMPARATOR
Intervention: Low-dose treatment (150 M)
Number of subjects: 20

Group type: COMPARATOR
Intervention: High-dose treatment (300 M)
Number of subjects: 20
Study: 26952309

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol
Number of subjects: 2331

Group type: COMPARATOR
Intervention: Formoterol
Number of subjects: 2331
Study: 24462483

Group type: EXPERIMENTAL
Intervention: Zinc (20 mg zinc sulfate for 14 days)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Albendazole (single dose)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study: 23147875

Group type: EXPERIMENTAL
Intervention: CPAP therapy every 2 hours (CPAP 2 hrs)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Incentive spirometry (IS) therapy
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: CPAP therapy every 4 hours (CPAP 4 hrs)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: All groups (CPAP 2 hrs, CPAP 4 hrs, IS)
Number of subjects: 108
Study: 19280112

Group type: EXPERIMENTAL
Intervention: Omeprazole 10 mg once daily for 2 weeks
Number of subjects: 130

Group type: COMPARATOR
Intervention: Famotidine 10 mg twice daily for 2 weeks
Number of subjects: 130

Group type: COMPARATOR
Intervention: Famotidine 10 mg twice daily for a third 2-week period
Number of subjects: 130
Study: 17192288

Group type: EXPERIMENTAL
Intervention: Tibolone 1.25 mg/d
Number of subjects: 3240

Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg/d
Number of subjects: 3240

Group type: COMPARATOR
Intervention: CEE/MPA (0.625 + 2.5 mg/d)
Number of subjects: 3240
Study: 15365707

Group type: EXPERIMENTAL
Intervention: Clozapine 100 mg/day
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Clozapine 300 mg/day
Number of subjects: 35

Group type: COMPARATOR
Intervention: Haloperidol 10 mg/day (4-week trial)
Number of subjects: 35
Study: 11259519

Group type: EXPERIMENTAL
Intervention: Safety equipment present during assessments of risk tolerance
Number of subjects: 151

Group type: COMPARATOR
Intervention: Safety equipment not present during assessments of risk tolerance
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Children in the presence of safety equipment
Number of subjects: 151

Group type: COMPARATOR
Intervention: Children in the absence of safety equipment
Number of subjects: 151
Study: 9700674

Group type: EXPERIMENTAL
Intervention: Cerebrolysin 10 ml
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Cerebrolysin (10 ml, 30 ml)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Cerebrolysin 50 ml
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (NaCl)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Cerebrolysin (all doses)
Number of subjects: 48
Study: 8305754

Group type: EXPERIMENTAL
Intervention: Topical application of EMLA cream
Number of subjects: 89

Group type: COMPARATOR
Intervention: Local infiltration with lignocaine
Number of subjects: 89
Study: 2903143

Group type: EXPERIMENTAL
Intervention: Clonazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 0
Study: 31714323

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine sedation
Number of subjects: 366

Group type: COMPARATOR
Intervention: Propofol sedation
Number of subjects: 366
Study: 30145391

Group type: EXPERIMENTAL
Intervention: Beck Depression Inventory (BDI‐II)
Number of subjects: 709

Group type: EXPERIMENTAL
Intervention: Patient Health Questionnaire (PHQ‐9)
Number of subjects: 709

Group type: EXPERIMENTAL
Intervention: General depression factors (BDI‐II and PHQ‐9)
Number of subjects: 709

Group type: EXPERIMENTAL
Intervention: Adjusted regression models
Number of subjects: 709
Study: 28265816

Group type: EXPERIMENTAL
Intervention: Morinidazole (500 mg twice daily for 14 days)
Number of subjects: 338

Group type: COMPARATOR
Intervention: Ornidazole (500 mg twice daily for 14 days)
Number of subjects: 338
Study: 25540268

Group type: EXPERIMENTAL
Intervention: Inactivated whole‐virus Vero cell culture‐derived RRV vaccine (2.5‐μg dose, Al(OH)(3)‐adjuvanted, with second and third doses after 3 weeks and 6 months)
Number of subjects: 1964

Group type: EXPERIMENTAL
Intervention: Inactivated whole‐virus Vero cell culture‐derived RRV vaccine
Number of subjects: 1964
Study: 22957911

Group type: EXPERIMENTAL
Intervention: Platform-switched implant-abutment connection (test)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Platform-matched implant-abutment connection (control)
Number of subjects: 92
Study: 20577111

Group type: EXPERIMENTAL
Intervention: Adjustable sutures
Number of subjects: 50

Group type: COMPARATOR
Intervention: Laser suture lysis
Number of subjects: 50
Study: 18315420

Group type: EXPERIMENTAL
Intervention: Nanocrystalline hydroxyapatite (NHA) paste
Number of subjects: 28

Group type: COMPARATOR
Intervention: Open flap debridement
Number of subjects: 28

Group type: COMPARATOR
Intervention: Comparison between NHA paste and open flap debridement
Number of subjects: 28
Study: 16573800

Group type: EXPERIMENTAL
Intervention: Lansoprazole 60‐mg intravenous bolus followed by 6‐mg/h continuous infusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lansoprazole 90‐mg intravenous bolus followed by 6‐mg/h continuous infusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lansoprazole 90‐mg intravenous bolus followed by 7.5‐mg/h continuous infusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lansoprazole 90‐mg intravenous bolus followed by 9‐mg/h continuous infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12452516

Group type: EXPERIMENTAL
Intervention: Combination of metronidazole and povidone iodine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Povidone iodine alone
Number of subjects: 50
Study: 10511022

Group type: EXPERIMENTAL
Intervention: Brinzolamide 1% ophthalmic suspension
Number of subjects: 25

Group type: COMPARATOR
Intervention: Dorzolamide 2% ophthalmic solution
Number of subjects: 25
Study: 7861825

Group type: EXPERIMENTAL
Intervention: AVIVA - a talking computer that assesses health risk, gives priorities for risk reduction, discusses risk reduction methods, and refers callers to additional information.
Number of subjects: 96

Group type: COMPARATOR
Intervention: Health information from magazines, television, or health professionals.
Number of subjects: 96
Study: 2387667

Group type: EXPERIMENTAL
Intervention: Vitamin E (200 mg twice daily for 4 weeks)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 6122232

Group type: EXPERIMENTAL
Intervention: 800 mg propoxyphene napsylate (PN) in two divided doses
Number of subjects: 0

Group type: COMPARATOR
Intervention: 10 mg methadone
Number of subjects: 0

Group type: COMPARATOR
Intervention: 20 mg methadone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo methadone
Number of subjects: 0
Study: 31678446

Group type: EXPERIMENTAL
Intervention: EndoscopeRobot
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (without EndoscopeRobot)
Number of subjects: 30
Study: 30773772

Group type: EXPERIMENTAL
Intervention: Malted sorghum‐based porridge (MSBP)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Extruded maize and soy micronutrient fortified blend (CSB+)
Number of subjects: 220
Study: 28751226

Group type: EXPERIMENTAL
Intervention: short‐lasting tDCS (20 min) during training
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: long‐lasting tDCS (10 min-25 min break-10 min) one day before training
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: short‐lasting tDCS one day before training
Number of subjects: 80

Group type: COMPARATOR
Intervention: sham tDCS
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: BDNF Met allele presence
Number of subjects: 80
Study: 25770879

Group type: EXPERIMENTAL
Intervention: Ingenol mebutate gel (0.015% once daily for 3 days for face/scalp; 0.05% once daily for 2 days for trunk/extremities)
Number of subjects: 1005

Group type: EXPERIMENTAL
Intervention: Ingenol mebutate gel
Number of subjects: 1005

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 1005
Study: 25199059

Group type: EXPERIMENTAL
Intervention: Intravenous mepolizumab (75 mg every 4 weeks for 32 weeks)
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: Subcutaneous mepolizumab (100 mg every 4 weeks for 32 weeks)
Number of subjects: 576

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 576
Study: 21114680

Group type: EXPERIMENTAL
Intervention: Scaling and root planing (non-surgical periodontal therapy)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Delayed treatment (control group)
Number of subjects: 60
Study: 19526589

Group type: EXPERIMENTAL
Intervention: Temsirolimus (25 mg intravenously weekly)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interferon-alpha (3 million U subcutaneously 3x weekly, escalating to 18 MU)
Number of subjects: 0
Study: 17511767

Group type: EXPERIMENTAL
Intervention: Duloxetine 80 mg/day for 4 weeks increased to 120 mg/day for 8 weeks
Number of subjects: 306

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study: 15370730

Group type: EXPERIMENTAL
Intervention: Rehabilitation (group A)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (group B)
Number of subjects: 20
Study: 16493377

Group type: EXPERIMENTAL
Intervention: Hypocaloric balanced diet therapy with antioxidant and ω-3 supplementation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Hypocaloric balanced diet therapy
Number of subjects: 40
Study: 9190351

Group type: EXPERIMENTAL
Intervention: Manual vacuum aspiration (MVA)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Dilation and curettage (D&C)
Number of subjects: 248
Study: 8352625

Group type: EXPERIMENTAL
Intervention: Pulsed low-intensity direct current (300 to 600 microA)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Sham instrument (placebo group)
Number of subjects: 74
Study: 3610329

Group type: EXPERIMENTAL
Intervention: Intravenous (i.v.) injection of 1 g cefpirome
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intramuscular (i.m.) injection of 1 g cefpirome
Number of subjects: 10

Group type: COMPARATOR
Intervention: Intravenous (i.v.) and Intramuscular (i.m.) injections of 1 g cefpirome
Number of subjects: 10
Study: 31509850

Group type: EXPERIMENTAL
Intervention: Dapsone
Number of subjects: 175
Study: 31574087

Group type: EXPERIMENTAL
Intervention: Malaria infection before 24 weeks gestation
Number of subjects: 1628

Group type: EXPERIMENTAL
Intervention: Malaria positive only before week 24
Number of subjects: 1628

Group type: EXPERIMENTAL
Intervention: Malaria before 24 weeks gestation
Number of subjects: 1628
Study: 28282005

Group type: EXPERIMENTAL
Intervention: Omentoplasty
Number of subjects: 124

Group type: COMPARATOR
Intervention: Nonomentoplasty
Number of subjects: 124
Study: 25352437

Group type: EXPERIMENTAL
Intervention: 2RDA (1.5 g·kg(‐1)·day(‐1))
Number of subjects: 20

Group type: COMPARATOR
Intervention: 1RDA (0.8 g·kg(‐1)·day(‐1))
Number of subjects: 20
Study: 23683639

Group type: EXPERIMENTAL
Intervention: Women's groups
Number of subjects: 26262

Group type: EXPERIMENTAL
Intervention: Peer counselling
Number of subjects: 26262
Study: 21310040

Group type: EXPERIMENTAL
Intervention: Maximal bronchodilation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (undilated condition)
Number of subjects: 40
Study: 19342506

Group type: EXPERIMENTAL
Intervention: Pexacerfont 25 mg qd
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Pexacerfont 100 mg qd
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 16478794

Group type: EXPERIMENTAL
Intervention: Etoposide-cisplatin chemotherapy
Number of subjects: 54
Study: 15270741

Group type: EXPERIMENTAL
Intervention: Family unit treatment (all infected family members treated)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Index case treatment (index case only treated)
Number of subjects: 50
Study: 10985630

Group type: EXPERIMENTAL
Intervention: Nickel sulfate patch tests at 1, 3, and 7 cm distance from potassium dichromate patches
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: Nickel sulfate patch tests at 1 cm distance from potassium dichromate patches
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: Nickel sulfate patch tests
Number of subjects: 589
Study: 9087680

Group type: EXPERIMENTAL
Intervention: L-NMMA (3 mg/kg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 8
Study: 8364286

Group type: EXPERIMENTAL
Intervention: Antimicrobial drugs (AMDs) prescribed to hospitalized children
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Oxacillin
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Other pharmacotherapeutic categories
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Length of stay
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Age group (1-year group)
Number of subjects: 1000
Study: 3511372

Group type: EXPERIMENTAL
Intervention: Intravenous cyclophosphamide plus low-dose prednisone
Number of subjects: 107

Group type: COMPARATOR
Intervention: High-dose oral prednisone alone
Number of subjects: 107
Study: 3293827

Group type: EXPERIMENTAL
Intervention: Chloroquine (25 mg/kg body weight)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Amodiaquine (25 mg/kg)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Sulfadoxine‐pyrimethamine (25 mg/kg and 1.25 mg/kg)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Amodiaquine (25 mg/kg) + sulfadoxine‐pyrimethamine (25 mg/kg and 1.25 mg/kg)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Sulfadoxine‐pyrimethamine alone
Number of subjects: 200
Study: 31222778

Group type: EXPERIMENTAL
Intervention: Nurse-led assessment and care planning intervention for frail older people
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual primary care for frailty
Number of subjects: 60
Study: 29066876

Group type: EXPERIMENTAL
Intervention: Threshold inspiratory muscle training (IMT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Expiratory muscle training (EMT)
Number of subjects: 40
Study: 25138579

Group type: EXPERIMENTAL
Intervention: Tamsulosin OCAS 0.4 mg and desmopressin MELT 60 mcg (D/T group)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Tamsulosin OCAS 0.4 mg only (T group)
Number of subjects: 248
Study: 22802301

Group type: EXPERIMENTAL
Intervention: Logo-autobiography (LA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (with antidepressants)
Number of subjects: 40
Study: 21791883

Group type: EXPERIMENTAL
Intervention: Combination of VerifyNow P2Y12 (PRU) and Aspirin (ARU) testing
Number of subjects: 716

Group type: COMPARATOR
Intervention: Tertiles of ARU
Number of subjects: 716

Group type: COMPARATOR
Intervention: Tertiles of PRU
Number of subjects: 716

Group type: EXPERIMENTAL
Intervention: Highest tertile of the sum of ARU and PRU tertiles
Number of subjects: 716
Study: 18343158

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Recovered Tennis Elbow (RTE)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Tennis Elbow (TE)
Number of subjects: 21
Study: 17361920

Group type: EXPERIMENTAL
Intervention: Bicalutamide 150 mg/day orally
Number of subjects: 8113

Group type: EXPERIMENTAL
Intervention: Adjuvant hormonal therapy (bicalutamide)
Number of subjects: 8113

Group type: EXPERIMENTAL
Intervention: Adjuvant bicalutamide
Number of subjects: 8113

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8113
Study: 15293174

Group type: EXPERIMENTAL
Intervention: Telephone follow-up by a nurse researcher
Number of subjects: 238
Study: 11153668

Group type: EXPERIMENTAL
Intervention: Indinavir (IDV)
Number of subjects: 171